| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/02/2004 | EP1373249A1 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent |
| 01/02/2004 | EP1373248A1 Benzimidazol derivatives modulate chemokine receptors |
| 01/02/2004 | EP1373247A2 Spiroisoquinoline compounds, methods for their preparation and intermediates thereof |
| 01/02/2004 | EP1373242A1 Dimeric isoflavones |
| 01/02/2004 | EP1373240A2 Retinoid x receptor modulators |
| 01/02/2004 | EP1373233A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 01/02/2004 | EP1373224A1 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 01/02/2004 | EP1373223A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 01/02/2004 | EP1373220A1 Benzimidazoles that are useful in treating sexual dysfunction |
| 01/02/2004 | EP1373218A1 Imidazolyl derivatives useful as histamine h3 receptor ligands |
| 01/02/2004 | EP1373217A1 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors |
| 01/02/2004 | EP1373216A1 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 01/02/2004 | EP1373206A1 Aryl oxime-piperazines useful as ccr5 antagonists |
| 01/02/2004 | EP1373205A1 Novel piperidine derivatives as modulators of chemokine receptors |
| 01/02/2004 | EP1373204A2 Heterocyclic compounds |
| 01/02/2004 | EP1373203A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 01/02/2004 | EP1373191A1 Acylated indanyl amines and their use as pharmaceuticals |
| 01/02/2004 | EP1373188A1 Alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics |
| 01/02/2004 | EP1373185A2 Hydrophobic polyamine analogs and methods for their use |
| 01/02/2004 | EP1373166A2 Supercritical hydrogenation |
| 01/02/2004 | EP1372785A2 Compositions having improved bioavailability of eletriptan |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372733A2 Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration |
| 01/02/2004 | EP1372703A2 Matrix stabilized enzyme crystals and methods of use |
| 01/02/2004 | EP1372696A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/02/2004 | EP1372695A2 Cell damage inhibitor |
| 01/02/2004 | EP1372684A1 Methods of reducing beta-amyloid polypeptides |
| 01/02/2004 | EP1372682A2 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
| 01/02/2004 | EP1372681A1 Biologically active chloroform fraction of an extract obtained from a mangrove plant salvadora persica l |
| 01/02/2004 | EP1372676A1 Pharmaceutical composition comprising copper, salicylic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection |
| 01/02/2004 | EP1372664A1 Use of certain steroids for treatment of blood cell deficiencies |
| 01/02/2004 | EP1372656A1 Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors |
| 01/02/2004 | EP1372654A2 Quinoline inhibitors of hyak1 and hyak3 kinases |
| 01/02/2004 | EP1372651A1 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity |
| 01/02/2004 | EP1372647A2 Use of substituted imidazo 1,2-a]-pyridine compounds as medicaments |
| 01/02/2004 | EP1372644A2 Use of substituted imidazo 1,2-a]-pyridine-3-yl-amide and imidazo 1,2-a]-pyridine-3-yl-amine compounds as medicaments |
| 01/02/2004 | EP1372640A2 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof |
| 01/02/2004 | EP1372638A1 Functional role for cannabinoids in autonomic stability during sleep |
| 01/02/2004 | EP1372635A1 Use of creatine for the amelioration of oxidative stress |
| 01/02/2004 | EP1372634A2 Fumaric acid amides |
| 01/02/2004 | EP1372627A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/02/2004 | EP1372626A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 01/02/2004 | EP1372625A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors |
| 01/02/2004 | EP1372624A2 Tramadol-based medicament |
| 01/02/2004 | EP1372620A2 Methods for restoring cognitive function following systemic stress |
| 01/02/2004 | EP1372392A1 Nicotine-containing oral dosage form |
| 01/02/2004 | EP1235830B1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS |
| 01/02/2004 | EP1027339B1 Method and reagents for n-alkylating ureides |
| 01/01/2004 | US20040003425 Nav2 channel gene-deficient non-human animals |
| 01/01/2004 | US20040002608 Central nervous system disorders |
| 01/01/2004 | US20040002540 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 01/01/2004 | US20040002537 Multiple sclerosis; central nervous system disorders; side effect reduction |
| 01/01/2004 | US20040002534 Stem cell factor; signal transduction passageways; anticancer agents |
| 01/01/2004 | US20040002524 Cardiovascular disorders; osteoporosis; central nervous system disorders |
| 01/01/2004 | US20040002523 Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
| 01/01/2004 | US20040002522 Antiinflammatory agents; analgesics |
| 01/01/2004 | US20040002517 Alzheimer's disease |
| 01/01/2004 | US20040002512 Alpha-substituted carboxylic acid derivatives |
| 01/01/2004 | US20040002511 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators |
| 01/01/2004 | US20040002508 Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders |
| 01/01/2004 | US20040002507 Rho-kinase inhibitors |
| 01/01/2004 | US20040002503 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 01/01/2004 | US20040002493 Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient |
| 01/01/2004 | US20040002491 Melatonergic receptors |
| 01/01/2004 | US20040002490 Melatonergic receptors |
| 01/01/2004 | US20040002482 Androgen pharmaceutical composition and method for treating depression |
| 01/01/2004 | US20040002478 Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
| 01/01/2004 | US20040002473 Pain modulation; incotinence therapy; central nervous system disorders |
| 01/01/2004 | US20040002460 Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom |
| 01/01/2004 | US20040002446 Central nervous system disorders; brain disorders; administering genetic engineered thrombomodulin |
| 01/01/2004 | US20040002439 Human voltage gated sodium channel beta1A subunit and methods of use |
| 01/01/2004 | US20040002423 Remedies |
| 01/01/2004 | US20040002134 Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides |
| 01/01/2004 | US20040002088 Identification and isolation of novel DNA and to the recombinant production of polypeptides having sequence similarity to Glial Cell line-derived Neurotrophic Factor Receptor (GDNFR) |
| 01/01/2004 | US20040001896 Plant extracts |
| 01/01/2004 | US20040001895 Combination treatment for depression and anxiety |
| 01/01/2004 | US20040001824 Cell proliferation inhibitors |
| 12/31/2003 | WO2004001424A1 Materials and methods for inductions of immune tolerance |
| 12/31/2003 | WO2004001068A2 Use of pp2a phosphatase modulators in the treatment of mental disorders |
| 12/31/2003 | WO2004001038A1 Novel gene and protein participating in neuralization of cells or tissues and utilization thereof |
| 12/31/2003 | WO2004001021A1 Pasteurisation process for microbial cells and microbial oil |
| 12/31/2003 | WO2004001014A2 Osteopontin, oligodendrocytes and myelination |
| 12/31/2003 | WO2004000887A1 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same |
| 12/31/2003 | WO2004000877A2 Peptides derived from the rabies virus glycoprotein g, ligands of the low-affinity receptor of neurotrophins (p75ntr) and applications thereof |
| 12/31/2003 | WO2004000875A2 Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders |
| 12/31/2003 | WO2004000854A1 Sulfur-containing phospholipid derivatives |
| 12/31/2003 | WO2004000849A2 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| 12/31/2003 | WO2004000846A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 12/31/2003 | WO2004000845A1 Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 12/31/2003 | WO2004000843A1 NOVEL PURINE- OR PYRROLOL[2,3-d]PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY |
| 12/31/2003 | WO2004000841A1 Hetero-bicyclic compounds |
| 12/31/2003 | WO2004000840A2 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 12/31/2003 | WO2004000839A1 Thiazole derivatives as phosphodiesterase iv inhibitors |
| 12/31/2003 | WO2004000837A1 Novel benzoxazolinone derivative |
| 12/31/2003 | WO2004000833A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase |
| 12/31/2003 | WO2004000832A1 1-[(indol-3-yl)carbonyl] piperazine derivatives |
| 12/31/2003 | WO2004000831A1 Indole derivatives useful as histamine h3 antagonists |
| 12/31/2003 | WO2004000830A1 Novel compounds, their use and preparation |
| 12/31/2003 | WO2004000829A1 Novel process |
| 12/31/2003 | WO2004000828A1 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |